Please login to the form below

Not currently logged in
Email:
Password:

GSK's Promacta granted full US approval

The US Food and Drug Administration has granted approval to GSK's Promacta, used to raise platelet counts in patients with a rare blood disorder

The US Food and Drug Administration (FDA) has granted full marketing approval to GlaxoSmithKline's (GSK) Promacta (eltrombopag), an oral tablet that is used to raise platelet counts in patients with a rare blood disorder.

Promacta, which was granted provisional clearance under the agency' accelerated approval programme in late 2008, is approved for patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Chronic ITP is a serious disease marked by increased platelet destruction and/or inadequate platelet production in the blood, leading to an increased risk of bruising and bleeding.

"Promacta is a testament to how the FDA Accelerated Approval Programme supports development of therapies that meet unmet patient needs," said Steven Stein, vice president of Medicines Development at GSK. "Patients with limited treatment options gained access to Promacta while GSK conducted clinical studies that yielded additional efficacy and safety data."

Promacta's labelling is being updated to include efficacy and safety data from a six- month study showing that patients treated with the drug were significantly more likely to achieve the study's targeted platelet count during the entire six-month period than were the patients on placebo.

Promacta was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals. GSK developed the product and has exclusive worldwide rights, with Ligand standing to receive milestone payments and royalties.

In May 2010, GSK halted a study of the drug in patients with thrombocytopaenia related to chronic liver disease after the treatment was linked to an increased risk for portal venous thrombosis in that population.

28th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics